RE: Another deal9 Jun 2026 17:04
Do you think the delay in completing the Celea financing was intentional, aimed at allowing time for a bidder to submit an offer? Robert Lyne may favour a takeover bid over an unfavourable financing arrangement, and given the current M&A landscape in biotechnology, a bid could be imminent. A large pharmaceutical player or private equity firm would likely be a more suitable partner for Seaport than a struggling company that is not listed on Nasdaq and is trading close to all-time lows in LSE.